Business
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. “Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness,” sai
About this update from Plus Therapeutics, Inc.
[{"type":"image","alt":"Plus Therapeutics Inc.","displaySize":"","headline":null,"caption":"Plus Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":172,"url":"https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iUBJ3sPkI4ud4lMmyJb.Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c","width":300,"height":172}},"lazy":false},{"type":"text","content":"Expands CNSide Clinical License in State of Pennsylvania","length":56,"tagName":"p"},{"type":"text","content":"HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization.","length":346,"tagName":"p"},{"type":"text","content":"“Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness,” said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. “Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027.”","length":330,"tagName":"p"},{"type":"text","content":"Overview of anticipated company milestones for 2026:","length":52,"tagName":"p"},{"type":"text","content":"REYOBIQ clinical program:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Define optimal dose/interval for REYOBIQ in the ReSPECT-LM Phase 2 trial; anticipate reporting data in Q3 2026","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Completing enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma and conduct an end of phase meeting with the FDA to align on pivotal trial design, with data expected in Q4 2026","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Complete commercial manufacturing scale up for REYOBIQ","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"Begin enrollment in the ReSPECT-PBC pediatric brain cancer Phase 1 trial","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":420,"olType":false},{"t...